Vandetanib for aggressive and symptomatic medullary thyroid cancer
Deshpande H, Carling T, Khan N, Holt E. Vandetanib for aggressive and symptomatic medullary thyroid cancer. Journal Of Clinical Practice 2013, 10: 275-282. DOI: 10.2217/cpr.13.17.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerSymptomatic medullary thyroid cancerMetastatic medullary thyroid cancerNew tyrosine kinase inhibitorsThyroid cancer accountsTyrosine kinase inhibitorsAggressive metastatic formsGrowth factor receptorProto-oncogene RETCancer accountsClinical trialsSignificant symptomsMetastatic formSporadic formsMalignant cellsUS FDAClinical useVandetanibKinase inhibitorsFactor receptorCancerFirst agentPhase IIDisease